Novel targeted therapies in head and neck cancer

Expert Opinion on Investigational Drugs

Volumn 21, Issue 3, 2012, Pages 281-295

  Ferreira, Mariana B A ^a   Lima, João Paulo S N ^a   Cohen, Ezra E W ^b  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

AKT; Angiogenesis; EGFR; Head and neck cancer

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CRIZOTINIB; DASATINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; FLUOROURACIL; FORETINIB; GEFITINIB; GPI 15427; INIPARIB; LAPATINIB; METHOTREXATE; MK 2206; NIRAPARIB; OLAPARIB; PACLITAXEL; PANITUMUMAB; PEMETREXED; RAPAMYCIN; RIDAFOROLIMUS; RUCAPARIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; XL 147; ZALUTUMUMAB;

ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ASTHENIA; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CELL INVASION; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; DNA REPAIR; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DYSPHAGIA; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENE AMPLIFICATION; GENE MUTATION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; INFECTION; INTENSITY MODULATED RADIATION THERAPY; KAPOSI SARCOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; RASH; RECURRENT CANCER; REVIEW; SEPSIS; SEVERE CONGENITAL NEUTROPENIA; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; TRACHEAL HEMORRHAGE; TUMOR BLEEDING; VOMITING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

EID: 84856872046     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.651455     Document Type: Review

References (133)

1. Moon C, Chae YK, Lee J. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab. Exp Biol Med (Maywood) 2010;235(8):907-20
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24(14):2137-50 (Pubitemid 46655601)
3. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003;129(1):106-12 (Pubitemid 36070885)
4. Hopkins J, Cescon DW, Tse D, et al. Genetic polymorphisms and head and neck cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev 2008;17(3):490-9 (Pubitemid 351469197)
5. Cloos J, Spitz MR, Schantz SP. Genetic susceptibility to head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88(8):530-5 (Pubitemid 26118723)
6. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9-22
7. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(17):2644-52 (Pubitemid 46628471)
8. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(15):3562-7
9. Goerner M, Seiwert TY, Sudhoff H. Molecular targeted therapies in head and neck cancer-an update of recent developments. Head Neck Oncol 2:8
10. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009;60:207-19
11. Harrington KJ, Kazi R, Bhide SA, et al. Novel therapeutic approaches to squamous cell carcinoma of the head and neck using biologically targeted agents. Indian J Cancer 2010;47(3):248-59
12. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003;39(10):1348-54 (Pubitemid 36773776)
13. Ang K, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62(24):7350-6 (Pubitemid 36025259)
14. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13(2):132-9
15. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11(10):1873-8 (Pubitemid 23304610)
16. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78(6):1284-92 (Pubitemid 26303896)
17. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53(15):3579-84 (Pubitemid 23229640)
18. Rubin Grandis J, Tweardy DJ, Melhem MF. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998;4(1):13-20 (Pubitemid 28062872)
19. Klinghammer K, Knödler M, Schmittel A, et al. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res 2011;16(1):304-10
20. Cohen EE, Lingen MW, Martin LE, et al. Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res 2005;11(22):8105-8 (Pubitemid 41698754)
21. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22(1):77-85 (Pubitemid 41095117)
22. Sos ML, Koker M, Weir BA, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 2009;69(8):3256-61
23. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002;7(Suppl 4):31-9 (Pubitemid 34977161)
24. Gullick WJ. The Type 1 growth factor receptors and their ligands considered as a complex system. Endocr Relat Cancer 2001;8(2):75-82 (Pubitemid 32641350)
25. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-8 (Pubitemid 32938123)
26. Lui VW JR. Grandis, EGFR-mediated cell cycle regulation. Anticancer Res 2002;22(1A):1-11
27. Zhang H, Alan Berezov A, Wang Q, et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007;117(8):2051-8 (Pubitemid 47224766)
28. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21(14):2787-99 (Pubitemid 46606324)
29. Modjtahedi H, Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009;20(10):851-5
30. Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001;49(2):427-33 (Pubitemid 32120240)
31. Barnes CJ, Kumar R. Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets. Cancer Metastasis Rev 2003;22(4):301-7 (Pubitemid 36791888)
32. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6(6):2166-74 (Pubitemid 30399181)
33. Herbst RS, Kim ES, Harari PM. IMCC225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1(4):719-32 (Pubitemid 33769082)
34. Huang SM, Li J, Harari PM. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther 2002;1(7):507-14
35. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7(9):493-507
36. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354(6):567-78 (Pubitemid 43209104)
37. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8
38. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27
39. Frampton JE. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 2010;70(15):1987-2010
40. Ang KK, Zhang Q, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). In American Society of Clinical Oncology annual meeting; Chicago, IL;2011
41. Sok JC, Copelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006;12(17):5064-73 (Pubitemid 44453332)
42. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010;16(9):2489-95
43. Batra SK, Castelino-Prabhu S, Wikstrand CJ, et al. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 1995;6(10):1251-9
44. Carteni G, Fiorentino R, Vecchione L, et al. Panitumumab a novel drug in cancer treatment. Ann Oncol 2007;18(Suppl 6):vi16-21
45. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010;21(2):342-7
46. Bhide SA, Nutting CM. Advances in chemotherapy for head and neck cancer. Oral Oncol 2010;46(6): 436-8
47. Vermorken JB, Stohlmacher J, Davidenko I, et al. Primary Efficacy and Safety Results of Spectrum, a Phase 3 Trial in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Receiving Chemotherapy with or without Panitumumab. In European Society for Medical Oncology Congress; Milan, Italy; 2010
48. Bastholt L, Specht L, Jensen K. Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck. Radiother Oncol 2007;85(1):24-8 (Pubitemid 47562580)
49. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2009;28(1):21-8
50. Pytel D, Sliwinski T, Poplawski T, et al. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009;9(1):66-76
51. Cohen EE, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009;45(10):e155-60
52. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980-7 (Pubitemid 46606387)
53. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009;27(11):1864-71
54. Argiris A, Ghebremichael M, Gilbert J. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group (ECOG). In Annual meeting American Society of Clinical Oncology; Chicago, IL; 2009
55. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007;25(16):2178-83 (Pubitemid 46954640)
56. Kim ES, Kies MS, Glisson BS. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. In Annual Meeting of American Society of Clinical Oncology; Chicago, IL; 2007
57. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76 (Pubitemid 36749215)
58. Van Meter ME, Kim ES. Bevacizumab: current updates in treatment. Curr Opin Oncol 2010;22(6):586-91
59. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol 2009;10(3):247-57
60. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol 2011;29(9):1140-5
61. Argiris A, Kotsakis AP, Kim S, et al. Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC): Final results. In American Society of Clinical Oncology annual meeting; Chicago, IL; 2011
62. Saura C, Baselga J, Herbst R, et al. Antitumor activity of cediranib in patients with metastatic or recurrent head and neck cancer (HNC) or recurrent non-small cell lung cancer (NSCLC): an open-label exploratory study. J Clin Oncol 2009;27(15s):abstract 6023.
63. Gustafson DL, Frederick B, Merz AL, Raben D. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 2008;61(2):179-88 (Pubitemid 350160317)
64. Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007;17(2):289-95
65. Papadimitrakopoulou V, Heymach J, Frank SJ, et al. Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. In American Society of Clinical Oncology annual meeting; Chicago, IL; 2011
66. Williamson SK, Moon J, Huang CH, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010;28(20):3330-5
67. Choong NW, Kozloff M, Taber D, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs 2010;28(5):677-83
68. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim Biophys Acta 2002;1602(2):114-30 (Pubitemid 34521791)
69. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene 2000;19(49):5636-42
70. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100(3):293-6 (Pubitemid 30353084)
71. Bu R, Purushotham KR, Kerr M, et al. Alterations in the level of phosphotyrosine signal transduction constituents in human parotid tumors. Proc Soc Exp Biol Med 1996;211(3):257-64
72. Xi S, Zhang Q, Dyer KF, et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278(34):31574-83 (Pubitemid 37048335)
73. Johnson FM, Saigal B, Talpaz M, et al. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 2005;11(19 Pt 1):6924-32 (Pubitemid 41428750)
74. Brooks HD, Glisson BS, Bekele BN, et al. Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2009;27(15s):abstract 6022.
75. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999;342(Pt 2):249-68 (Pubitemid 29425344)
76. Tentori L, Portarena I, Graziani G. Potential clinical applications of poly (ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 2002;45(2):73-85 (Pubitemid 35425647)
77. Smith S. The world according to PARP. Trends Biochem Sci. 2001;26(3):174-9 (Pubitemid 32197577)
78. Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003;2(4):371-82
79. Delaney CA, Wang LZ, Kyle S, et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 2000;6(7):2860-7 (Pubitemid 30482128)
80. Griffin RJ, Curtin NJ, Newell DR, et al. The role of inhibitors of poly(ADPribose) polymerase as resistance-modifying agents in cancer therapy. Biochimie 1995;77(6):408-22
81. Bürkle A, Chen G, Küpper JH, et al. Increased poly(ADP-ribosyl)ation in intact cells by cisplatin treatment. Carcinogenesis 1993;14(4):559-61
82. Khan K, Araki K, Wang D, et al. Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 2010;32(3):381-91
83. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2001;127(7):411-17 (Pubitemid 32524357)
84. Chan G, Boyle JO, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59(5):991-4 (Pubitemid 29135955)
85. Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005;23(2):254-66 (Pubitemid 46206877)
86. Wirth LJ, Haddad RI, Lindeman NI, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23(28):6976-81
87. Choe MS, Chen Z, Klass CM, et al. Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13(10):3015-23 (Pubitemid 46849578)
88. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59(11):2615-22 (Pubitemid 29269108)
89. Goldberg AL, Stein R, Adams J. New insights into proteasome function: from archaebacteria to drug development. Chem Biol 1995;2(8):503-8
90. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem 1996;65:801-47 (Pubitemid 26255262)
91. Adams J, Palombella VJ, Sausville EA, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science 1989;243(4898):1576-83
92. King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science 1996;274(5293):1652-9 (Pubitemid 26414887)
93. Sherr CJ. Cancer cell cycles. Science 1996;274(5293):1672-7
94. Kubicek GJ, Machtay M, Axelrod RA, et al. Phase I trial of bortezomib (VELCADE), cisplatin and radiotherapy for advanced head and neck cancer. J Clin Oncol 2008;26(20 Suppl):abstract 6028.
95. Chung CH, Aulino J, Muldowney NJ, et al. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010;21(4):864-70
96. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006;24(11):1770-83 (Pubitemid 46628473)
97. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res 1996;68:67-108 (Pubitemid 26099813)
98. Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 2004;15(5):411-19 (Pubitemid 38736938)
99. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20(19):4074-82
100. Thomas JP, Tutsch KD, Cleary JF, et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002;50(6):465-72 (Pubitemid 35435525)
101. Yeo W, Goh B, Le Tourneau C, et al. A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol 2009;27(15s):abstract 6026.
102. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107(5):643-54 (Pubitemid 34014865)
103. Maulik G, Kijima T, Ma PC, et al. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res 2002;8(2):620-7 (Pubitemid 34193985)
104. Maulik G, Madhiwala P, Brooks S, et al. Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer. J Cell Mol Med 2002;6(4):539-53 (Pubitemid 44149770)
105. Comoglio PM, Trusolino L. Invasive growth: from development to metastasis. J Clin Invest 2002;109(7):857-62 (Pubitemid 34275105)
106. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat Rev Cancer 2002;2(4):289-300 (Pubitemid 37328782)
107. Christensen JG, Burrows J. Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 2005;225(1):1-26 (Pubitemid 40732764)
108. Knudsen BS, Vande Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008;18(1):87-96 (Pubitemid 351694452)
109. Gordon MS, Sweeney CS, Mendelson DS, et al. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. Clin Cancer Res 2010;16(2):699-710
110. Camacho LH, Bendell JC, John-Reid L, et al. Phase Ib dose-escalation trial evaluating c-MET inhibitor ARQ 197 administered in combination with gemcitabine to patients (pts) with advanced solid tumors. J Clin Oncol 2010;28(Suppl):abstract e13008
111. Seiwert T, Swann S, Kurz H, et al. A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5-days-on/9-days-off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck in AACR-NCI-EORTC. International Conference: Molecular Targets and Cancer Therapeutics; Boston, MA; 2009
112. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008;9(3):288-96 (Pubitemid 351722948)
113. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23 (Pubitemid 40411498)
114. Ekshyyan O, Rong Y, Rong X, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009;8(8):2255-65
115. Liao YM, Kim C, Yen Y. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007;67(5):2160-8
116. Jimeno A, Kulesza P, Wheelhouse J, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96(6):952-9 (Pubitemid 46452288)
117. Oh SH, Kim WY, Kim JH, et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12(2):653-61
118. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell 1993;72(1):73-84 (Pubitemid 23029694)
119. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84 (Pubitemid 44348499)
120. Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007;6(11):2967-75 (Pubitemid 350206775)
121. Blumenschein GR Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 2008;26(1):81-7
122. Préville X, Salvemini F, Giraud S, et al. Mammalian small stress proteins protect against oxidative stress through their ability to increase glucose-6-phosphate dehydrogenase activity and by maintaining optimal cellular detoxifying machinery. Exp Cell Res 1999;247(1):61-78 (Pubitemid 29393962)
123. Storm FK, Mahvi DM, Gilchrist KW. Heat shock protein 27 overexpression in breast cancer lymph node metastasis. Ann Surg Oncol 1996;3(6):570-3 (Pubitemid 126729008)
124. Thanner F, Sütterlin MW, Kapp M, et al. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res 2005;25(3A):1649-53 (Pubitemid 40896778)
125. Kassem HSH, Sangar V, Cowan R, et al. A potential role of heat shock proteins and nicotinamide N-methyl transferase in predicting response to radiation in bladder cancer. Int J Cancer 2002;101(5):454-60
126. Vargas-Roig LM, Gago FE, Tello O, et al. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79(5):468-75 (Pubitemid 28445267)
127. Lo WY, Tsai MH, Tsai Y, et al. Identification of over-expressed proteins in oral squamous cell carcinoma (OSCC) patients by clinical proteomic analysis. Clin Chim Acta 2007;376(1-2):101-7 (Pubitemid 44880973)
128. Victora GD, Socorro-Silva A, Volsi EC, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 2009;16(7):598-608
129. Yin X, Zhang H, Lundgren K, et al. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. Int J Cancer 2010;126(5):1216-25
130. Kefford R, Millward M, Hersey P, et al. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma. J Clin Oncol 2007;25(18s):abstract 8558.
131. Shillitoe EJ. Gene therapy: the end of the rainbow? Head Neck Oncol 2009;1:7
132. Brieger J, Mann SA, Pongsapich W et al. Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells. Int J Mol Med. 2012 Mar;29(3):505-9
133. Demokan S, Chuang A, Suoǵlu Y, et al. Promoter methylation and loss of p16 (INK4a) gene expression in head and neck cancer. Head Neck 2011 [Epub ahead of print]